Kenneth C. Kalunian

Nov 9, 2024 | lupus.bmj.com | Maria Dall'Era |Kenneth C. Kalunian |Neil Solomons

DiscussionThis analysis used propensity score methodology to compare early safety and efficacy outcomes associated with the voclosporin-based triple immunosuppressive regimen used in the AURA-LV and AURORA 1 studies with the high-dose GC-based dual immunosuppressive therapy regimens used in ALMS.

Sep 26, 2024 | reference.medscape.com | Kenneth C. Kalunian

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by multisystem inflammation and a relapsing and remitting disease course. It occurs most frequently in women and generally appears at childbearing age. SLE commonly affects the skin, joints, kidneys, blood cells, and nervous system.

Nov 13, 2023 | tullahomanews.com | Kenneth C. Kalunian

Your account has been registered, and you are now logged in. Check your email for details. An email message containing instructions on how to reset your password has been sent to the email address listed on your account. CAPTCHA Send Email × × Secure & Encrypted What's your email address? Who is this gift for? Optional message for the recipient Who is this gift from?

Oct 23, 2023 | manchestertimes.com | Kenneth C. Kalunian

LA JOLLA, Calif.--(BUSINESS WIRE)--Oct 19, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that abstracts were accepted for poster presentations at the annual meetings of the American Society of Nephrology (ASN) and the American College of Rheumatology (ACR).